AR095372A1 - Terapia de inducción con rituximab seguida por una terapia con acetato de glatiramer - Google Patents
Terapia de inducción con rituximab seguida por una terapia con acetato de glatiramerInfo
- Publication number
- AR095372A1 AR095372A1 ARP140100911A ARP140100911A AR095372A1 AR 095372 A1 AR095372 A1 AR 095372A1 AR P140100911 A ARP140100911 A AR P140100911A AR P140100911 A ARP140100911 A AR P140100911A AR 095372 A1 AR095372 A1 AR 095372A1
- Authority
- AR
- Argentina
- Prior art keywords
- subject
- certain amount
- treating
- glatiramer acetate
- multiple sclerosis
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
- A61J1/05—Containers specially adapted for medical or pharmaceutical purposes for collecting, storing or administering blood, plasma or medical fluids ; Infusion or perfusion containers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/03—Peptides having up to 20 amino acids in an undefined or only partially defined sequence; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Dermatology (AREA)
- Endocrinology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Hematology (AREA)
- Rheumatology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Pain & Pain Management (AREA)
- Transplantation (AREA)
- Obesity (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Psychiatry (AREA)
- Emergency Medicine (AREA)
Abstract
Método para tratar un sujeto que padece esclerosis múltiple o que padece un síndrome clínicamente aislado, que está basado en al menos dos administraciones periódicas de una cantidad determinada de rituximab, seguidas por la administración periódica de una cantidad determinada de acetato de glatiramer, donde las cantidades son eficaces para tratar el sujeto. Método para tratar un sujeto afectado por una enfermedad relacionada con la inmunidad, que también está basado en al menos dos administraciones periódicas de una cantidad determinada de rituximab, seguidas por la administración periódica de una cantidad determinada de acetato de glatiramer, donde las cantidades también son eficaces para tratar el sujeto, y donde la enfermedad relacionada con la inmunidad es una enfermedad autoinmune, una afección relacionada con la artritis, una enfermedad relacionada con la inflamación, la esclerosis múltiple, la esclerosis múltiple recurrente, la diabetes mellitus, la psoriasis, la artritis reumática, la enfermedad intestinal inflamatoria, la enfermedad de Crohn o el lupus eritematoso sistémico. Reivindicación 70: El uso del acetato de glatiramer, caracterizado porque es en la manufactura de un medicamento útil para tratar una forma de la esclerosis múltiple o un síndrome clínicamente aislado en un sujeto, que está basado en al menos dos administraciones periódicas de una cantidad determinada de rituximab, seguidas por la administración periódica de una cantidad determinada de acetato de glatiramer, donde las cantidades son eficaces para tratar el sujeto. Reivindicación 71: El uso de un anticuerpo anti-CD20, caracterizado porque es en la manufactura de un medicamento útil para tratar una forma de la esclerosis múltiple o un síndrome clínicamente aislado en un sujeto, que está basado en al menos dos administraciones periódicas de una cantidad determinada de rituximab, seguidas por la administración periódica de una cantidad determinada de acetato de glatiramer, donde las cantidades son eficaces para tratar el sujeto. Reivindicación 72: Una composición farmacéutica caracterizada porque comprende una cantidad determinada de acetato de glatiramer, que es útil para aliviar los síntomas de una forma de la esclerosis múltiple o de un síndrome clínicamente aislado en un sujeto cuando se la combina con un anticuerpo anti-CD20, donde el procedimiento comprende llevar a cabo al menos dos administraciones periódicas de una cantidad determinada de rituximab, seguidas por la administración periódica de una cantidad determinada de acetato de glatiramer, donde las cantidades son eficaces para tratar el sujeto. Reivindicación 74: Un conjunto de elementos caracterizado porque comprende (a) una primera composición farmacéutica que comprende una cantidad determinada de un anticuerpo anti-CD20 y un vehículo farmacéuticamente aceptable; (b) una segunda composición farmacéutica que comprende una cantidad determinada de acetato de glatiramer y un vehiculo farmacéuticamente aceptable; y (c) instrucciones para usar la primera composición farmacéutica y la segunda composición farmacéutica en el tratamiento de un paciente humano que padece una esclerosis múltiple recurrente o que padece un síndrome clínicamente aislado.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361778016P | 2013-03-12 | 2013-03-12 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR095372A1 true AR095372A1 (es) | 2015-10-14 |
Family
ID=51527961
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP140100911A AR095372A1 (es) | 2013-03-12 | 2014-03-12 | Terapia de inducción con rituximab seguida por una terapia con acetato de glatiramer |
Country Status (18)
| Country | Link |
|---|---|
| US (3) | US20160022811A1 (es) |
| EP (1) | EP2968559A4 (es) |
| JP (1) | JP2016512552A (es) |
| KR (1) | KR20150138240A (es) |
| CN (1) | CN105188751A (es) |
| AR (1) | AR095372A1 (es) |
| AU (1) | AU2014248524A1 (es) |
| BR (1) | BR112015022538A2 (es) |
| CA (1) | CA2903127A1 (es) |
| CL (1) | CL2015002597A1 (es) |
| EA (1) | EA201591687A1 (es) |
| HK (2) | HK1218253A1 (es) |
| IL (1) | IL240355A0 (es) |
| MX (1) | MX2015012156A (es) |
| PE (1) | PE20151937A1 (es) |
| TW (1) | TW201521757A (es) |
| WO (1) | WO2014165280A1 (es) |
| ZA (1) | ZA201507489B (es) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2949335B1 (en) | 2009-08-20 | 2017-01-04 | Yeda Research & Development Company, Ltd. | Low frequency glatiramer acetate therapy |
| USRE49251E1 (en) | 2010-01-04 | 2022-10-18 | Mapi Pharma Ltd. | Depot systems comprising glatiramer or pharmacologically acceptable salt thereof |
| PL2627669T3 (pl) | 2010-10-11 | 2017-02-28 | Teva Pharmaceutical Industries Ltd. | Biomarkery cytokinowe jako biomarkery prognostyczne odpowiedzi klinicznej na octan glatirameru |
| EP2765857A4 (en) | 2011-10-10 | 2015-12-09 | Teva Pharma | SIMPLE NUCLEOTIDE POLYMORPHISMS USEFUL FOR PREDICTING CLINICAL RESPONSE TO GLATIRAMERATE ACETATE |
| US9617596B2 (en) | 2012-10-10 | 2017-04-11 | Teva Pharmaceutical Industries, Ltd. | Biomarkers predictive for clinical response for glatiramer acetate |
| UY35790A (es) | 2013-10-21 | 2015-05-29 | Teva Pharma | Marcadores genéticos que predicen la respuesta al acetato de glatiramer |
| US9155775B1 (en) | 2015-01-28 | 2015-10-13 | Teva Pharmaceutical Industries, Ltd. | Process for manufacturing glatiramer acetate product |
| US9744920B2 (en) * | 2015-04-21 | 2017-08-29 | Mazda Motor Corporation | Noise insulation structure of cabin floor |
| US12097292B2 (en) | 2016-08-28 | 2024-09-24 | Mapi Pharma Ltd. | Process for preparing microparticles containing glatiramer acetate |
| BR112019017724A2 (pt) | 2017-03-26 | 2020-03-31 | Mapi Pharma Ltd. | Sistemas depot de glatiramer para tratar formas progressivas de esclerose múltipla |
| WO2019110643A1 (en) * | 2017-12-05 | 2019-06-13 | Mabion Sa | Combination therapy of multiple sclerosis comprising a cd20 ligand |
| US11814439B1 (en) * | 2022-06-01 | 2023-11-14 | Tg Therapeutics, Inc. | Anti-CD20 antibody compositions |
| US11884740B1 (en) | 2022-06-01 | 2024-01-30 | Tg Therapeutics, Inc. | Anti-CD20 antibody compositions |
| US11807689B1 (en) | 2022-06-01 | 2023-11-07 | Tg Therapeutics, Inc. | Anti-CD20 antibody compositions |
| US11965032B1 (en) | 2022-06-01 | 2024-04-23 | Tg Therapeutics, Inc. | Anti-CD20 antibody compositions |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BRPI0510915A (pt) * | 2004-06-04 | 2007-11-13 | Genentech Inc | método para o tratamento da esclerose múltipla e artigo manufaturado |
| US20070161566A1 (en) * | 2006-01-11 | 2007-07-12 | Teva Pharmaceutical Industries, Ltd. | Method of treating multiple sclerosis |
| AR078161A1 (es) * | 2009-09-11 | 2011-10-19 | Hoffmann La Roche | Formulaciones farmaceuticas muy concentradas de un anticuerpo anti cd20. uso de la formulacion. metodo de tratamiento. |
| EP2523668A1 (en) * | 2010-01-13 | 2012-11-21 | Ramot at Tel-Aviv University Ltd | Treatment of multiple sclerosis |
| US20130309229A1 (en) * | 2011-01-28 | 2013-11-21 | The United States Government As Represented By The Department Of Veterans Affairs | Recombinant t cell ligands and antibodies that bind b cells for the treatment of autoimmune diseases |
-
2014
- 2014-03-12 EA EA201591687A patent/EA201591687A1/ru unknown
- 2014-03-12 AR ARP140100911A patent/AR095372A1/es unknown
- 2014-03-12 WO PCT/US2014/025075 patent/WO2014165280A1/en active Application Filing
- 2014-03-12 EP EP14778696.6A patent/EP2968559A4/en not_active Withdrawn
- 2014-03-12 CA CA2903127A patent/CA2903127A1/en not_active Abandoned
- 2014-03-12 KR KR1020157028762A patent/KR20150138240A/ko not_active Application Discontinuation
- 2014-03-12 US US14/773,667 patent/US20160022811A1/en not_active Abandoned
- 2014-03-12 AU AU2014248524A patent/AU2014248524A1/en not_active Abandoned
- 2014-03-12 PE PE2015001971A patent/PE20151937A1/es not_active Application Discontinuation
- 2014-03-12 US US14/207,434 patent/US20140271630A1/en not_active Abandoned
- 2014-03-12 BR BR112015022538A patent/BR112015022538A2/pt not_active IP Right Cessation
- 2014-03-12 MX MX2015012156A patent/MX2015012156A/es unknown
- 2014-03-12 TW TW103108792A patent/TW201521757A/zh unknown
- 2014-03-12 CN CN201480014805.XA patent/CN105188751A/zh active Pending
- 2014-03-12 JP JP2016501737A patent/JP2016512552A/ja active Pending
-
2015
- 2015-08-04 IL IL240355A patent/IL240355A0/en unknown
- 2015-09-10 CL CL2015002597A patent/CL2015002597A1/es unknown
- 2015-10-08 ZA ZA2015/07489A patent/ZA201507489B/en unknown
-
2016
- 2016-06-02 HK HK16106268.4A patent/HK1218253A1/zh unknown
- 2016-06-24 HK HK16107400.1A patent/HK1219413A1/zh unknown
-
2017
- 2017-02-06 US US15/425,037 patent/US20170143824A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP2968559A1 (en) | 2016-01-20 |
| US20160022811A1 (en) | 2016-01-28 |
| EP2968559A4 (en) | 2016-11-02 |
| JP2016512552A (ja) | 2016-04-28 |
| IL240355A0 (en) | 2015-09-24 |
| ZA201507489B (en) | 2017-01-25 |
| KR20150138240A (ko) | 2015-12-09 |
| US20140271630A1 (en) | 2014-09-18 |
| HK1219413A1 (zh) | 2017-04-07 |
| MX2015012156A (es) | 2015-11-30 |
| CL2015002597A1 (es) | 2016-04-15 |
| US20170143824A1 (en) | 2017-05-25 |
| PE20151937A1 (es) | 2016-01-15 |
| HK1218253A1 (zh) | 2017-02-10 |
| AU2014248524A1 (en) | 2015-10-29 |
| TW201521757A (zh) | 2015-06-16 |
| CN105188751A (zh) | 2015-12-23 |
| WO2014165280A1 (en) | 2014-10-09 |
| EA201591687A1 (ru) | 2016-07-29 |
| CA2903127A1 (en) | 2014-10-09 |
| BR112015022538A2 (pt) | 2017-07-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR095372A1 (es) | Terapia de inducción con rituximab seguida por una terapia con acetato de glatiramer | |
| AR088458A1 (es) | Tratamiento de esclerosis multiple con la combinacion de laquinimod y fingolimod | |
| Tao et al. | Inhibition of Th1/Th17 responses via suppression of STAT1 and STAT3 activation contributes to the amelioration of murine experimental colitis by a natural flavonoid glucoside icariin | |
| MX2019013279A (es) | Metodos de tratamiento del sindrome de doose utilizando fenfluramina. | |
| RU2017115772A (ru) | Комбинация для генотерапии | |
| PE20151420A1 (es) | Una composicion para tratar diabetes o diabesidad que comprende un analogo de oxintomodulina | |
| PH12015502691A1 (en) | Use of high dose pridopidine for treating huntington's disease | |
| AR090885A1 (es) | Uso de laquinimod en alta dosis para el tratamiento de la esclerosis multiple | |
| AR077896A1 (es) | Terapia de baja frecuencia con acetato de glatiramer. uso. acetato de glatiramer. | |
| PE20142319A1 (es) | Tratamiento de esclerosis multiple con combinacion de laquinimod y acetato de glatiramero | |
| RU2017116740A (ru) | Комбинации для лечения рассеянного склероза | |
| RU2017134443A (ru) | Способ лечения с применением традипитанта | |
| EA202191079A1 (ru) | Способы лечения синдрома ретта с применением фенфлурамина | |
| MX2016011333A (es) | Sistemas de administracion de farmaco y metodo para el tratamiento de cancer de vejiga con gemcitabina. | |
| RU2015134422A (ru) | Применение левоцитиризина и монтелукаста при лечении васкулита | |
| PE20181332A1 (es) | Metodos de sedacion y formulacion parenteral para uso durante el tratamiento de cuidados criticos | |
| EA201592040A1 (ru) | Иммуногенная композиция для применения в терапии | |
| RU2015127834A (ru) | Способы лечения диабета путем введения антагониста рецептора глюкагона в сочетании с ингибитором поглощения холестерина | |
| NZ604009A (en) | A combination composition comprising ibuprofen and paracetamol | |
| EA201890101A1 (ru) | Новая схема лечения тиакумициновым соединением | |
| EA201592261A1 (ru) | Фармацевтические композиции, включающие агомелатин в форме сокристаллов агомелатина с органической кислотой | |
| Amadu | Kaposi’s sarcoma: case report | |
| EA201692107A1 (ru) | Схема лечения тиакумициновым соединением | |
| Nagy | Dalteparin sodium/nadroparin calcium | |
| AR122567A2 (es) | Terapia de baja frecuencia con acetato de glatiramer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |